Pharma & Life Sciences

Titanium-Reinforced PTFE vs PTFE Mesh Bone Augmentation

The National Library of Medicine registered a new randomized controlled trial (NCT07520903) comparing titanium-reinforced PTFE mesh to standard PTFE mesh for bone augmentation in dental implant procedures. The single-center study plans to enroll 80 participants with a 6-month follow-up period to evaluate graft stability and complication rates.

Phase I AD-230 Pharmacokinetics Study, Chronic Liver Disease

The National Library of Medicine's ClinicalTrials.gov registered NCT07521241, a Phase I study evaluating the pharmacokinetics of investigational drug AD-230 in patients with chronic liver disease. The trial collects PK parameters to characterize drug absorption, distribution, metabolism, and excretion in this population. This registry entry documents the study's design, eligibility criteria, and investigator information for public transparency.

NCT07519369: ASD Mobility Monitoring with Wrist Sensors

The National Library of Medicine registered a new clinical trial (NCT07519369) on ClinicalTrials.gov to evaluate mobility monitoring in individuals with Autism Spectrum Disorder (ASD) using wrist-worn sensors. The study is described as recruiting approximately 50 participants. ClinicalTrials.gov serves as a public registry of clinical research meeting applicable requirements.

HHS Proposed Rule Comment Submission Form

HHS is accepting public comments on a proposed rule through Regulations.gov. The submission form enables commenters to provide feedback up to 5,000 characters and attach supporting files, with the comment period closing May 8, 2025.

Nasal Cannabidiol Composition Patent, Frank-Markus Leweke, Apr 9

Nasal Cannabidiol Composition Patent, Frank-Markus Leweke, Apr 9

Cannabichromene COVID-19 ARDS Treatment Patent Application

The USPTO published patent application US20260097051A1 from Augusta University Research Institute claiming compositions comprising Cannabichromene (CBC) for treating COVID-19 ARDS. The application was filed August 18, 2025 and published April 9, 2026.

US20260098093A1, VISTA Molecules, Cancer Treatment, 9th Apr

US20260098093A1, VISTA Molecules, Cancer Treatment, 9th Apr

Multispecific Antibodies Targeting HLA-A2/MAGE-A4 Cancer Therapy

USPTO published Roche/Genentech patent application US20260098095A1 disclosing multispecific antibodies binding to HLA-A2/MAGE-A4 complex for T cell activation in cancer treatment. The application covers antibody compositions, encoding polynucleotides, production methods, and therapeutic uses. The invention addresses immunotherapy approaches for HLA-A2-positive tumors expressing MAGE-A4 antigen.

Anti-CCR8 Antibodies Therapeutic Agents Patent Application

USPTO published patent application US20260098096A1 for anti-CCR8 antigen binding proteins and fragments for detection and therapy of various conditions, including cancer. The application was filed September 21, 2023, by inventor Remy Michel Robert. CCR8 is a G-protein coupled receptor implicated in tumor immunosuppression.

Immunotoxin-Based Targeted Therapy for Cancer, CCR4 Bispecific

The USPTO published patent application US20260098097A1 for methods of treating cancer using a genetically engineered C-C motif chemokine receptor 4 (CCR4) bispecific immunotoxin. The application, filed December 29, 2023, covers treatment of cutaneous T-cell lymphoma and other cancers via administration of the immunotoxin alone or in combination with additional therapeutic agents such as antibody-drug conjugates.